Lalo Flores, Century Therapeutics CEO
Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century
Last to the game in the current generation of CAR-T cell therapies, Bristol Myers Squibb has wasted no time trying to challenge its closest rivals’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
